Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practice.
García-Rodríguez LA, Wallander MA, Friberg L, Ruigomez A, Schink T, Bezemer I, Herings R, Shakir S, Evans A, Davies M, Suzart-Woischnik K, Vora P, Balabanova Y, Soriano-Gabarró M, Brobert G.
García-Rodríguez LA, et al. Among authors: herings r.
Expert Opin Drug Saf. 2020 Nov;19(11):1513-1520. doi: 10.1080/14740338.2020.1798928. Epub 2020 Aug 4.
Expert Opin Drug Saf. 2020.
PMID: 32700977